
Pharmaceutical Technology Europe
- Pharmaceutical Technology Europe-09-01-2009
- Volume 21
- Issue 9
Digital Revolution
It's been a while since I last wrote my last editor's comment - a combination, during the last few months, of attending a variety of industry events (as the conference and exhibition season peaked before the summer) and being on holiday. I apologize for the poor excuses, but it's certainly better than saying the dog ate my homework.
It's been a while since I last wrote my last editor's comment — a combination, during the last few months, of attending a variety of industry events (as the conference and exhibition season peaked before the summer) and being on holiday. I apologize for the poor excuses, but it's certainly better than saying the dog ate my homework.
Gurminder Marwaha
I'd like to thank all those who participated in our annual readership survey a couple of months ago; your input and feedback is essential in helping us maintain Pharmaceutical Technology Europe (PTE) as the authoritative voice of the pharmaceutical industry. It's rewarding to know that we are providing the right balance of editorial and your comments will help us shape the magazine in 2007. Next year will see increased coverage of outsourcing and biopharmaceuticals — two key areas in this industry and, judging by your comments, ones that should be encompassed within PTE. And I must not forget to congratulate Nigel Miller of sanofi-aventis, who wins a Sony PSP for being picked out in the survey prize draw.
Already we're into September and it means there's only a few weeks to go until the CPhI expo in Paris. The show will see us launch our new electronic magazine, Pharmaceutical Technologist — a fully interactive digital publication that will offer a global insight with market analysis, showcase the latest industry trends, and offer commentary and opinions from leading people in the sector. And because it's available online in both live and downloadable easy-to-read formats, you'll always be able to keep up-to-date with what's happening in the industry at a time that suits you. If you'd like to contribute to this exciting reading experience, then just drop me an email at the address below.
We'll be sending out more information in due course, but if you would like to see Pharmaceutical Technologist in action, then drop by our stand at CPhI (Hall 5, Stand 5M39), where we'll have the launch issue set up and ready for you to view. We look forward to seeing you in Paris.
Articles in this issue
about 16 years ago
The combination drugs debate: unstable and unpatentableabout 16 years ago
Expansion planabout 16 years ago
The combination drugs debate: Incompatibility problems can be overcomeabout 16 years ago
Integrating PAT into biopharmaceutical research: a case studyabout 16 years ago
What to consider when expanding businesses into North Americaabout 16 years ago
Is another ODT excipient necessary?about 16 years ago
Embryonic stem cells: the moral dilemma of patentability and fundingabout 16 years ago
The benefits of risk-based analyses during system validationabout 16 years ago
NewsNewsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.





